Creative Biolabs Unveils Advanced Fc Engineering Platforms to Propel Next-Generation Therapeutic Antibodies
Summary
Creative Biolabs has expanded its Fc engineering suite for antibody developers working on next-generation immunotherapies. The platforms target Fc region modifications that can increase ADCC and CDC for oncology or silence effector functions for safer autoimmune and viral applications. The company also emphasizes maintaining FcRn binding so candidates keep favorable half-life and pharmacokinetics. Drug developers can use these services to optimize therapeutic antibodies and improve preclinical and clinical profiles.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected